Scientific Background
This dual-agonist blend combines amylin-receptor modulation (Cagrilintide) with GLP-1 receptor activation (Semaglutide), producing a powerful synergy explored in metabolic and weight-related research.
Mechanism of Action (Informational Only)

• Cagrilintide: amylin-receptor satiety signaling
• Semaglutide: GLP-1 receptor activation
• Dual influence on appetite-control pathways
• May enhance fat-oxidation signaling

Potential Functional Benefits

• High demand in weight-management studies
• Supports multi-pathway appetite regulation
• Often selected for metabolic-optimization research

Notes
For research and educational purposes only.